Skip to content

Assessing the effect of caffeine on attention in patients with and without dementia

Assessing the effect of caffeine on attention in patients with and without dementia: A double blind, randomised, cross over trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN78129879
Enrollment
40
Registered
2014-06-06
Start date
2014-07-01
Completion date
Unknown
Last updated
2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia with Lewy bodies, Parkinson's disease dementia, Alzheimer's dementia, vascular dementia, frontotemporal lobe dementia Mental and Behavioural Disorders Dementia

Interventions

A double blind crossover trial will compare instant coffee (a cup containing 1 standard sachet of approximately 4g Starbucks VIA Ready Brew Italian Roast with 250ml of hot water) with decaffeinated in

Sponsors

North Bristol NHS Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with dementia with Lewy bodies or Parkinson's disease dementia fulfilling standard diagnostic criteria who retain capacity to consent to research, in keeping with the Mental Capacity Act 2005 2. Patients on or off cholinesterase inhibitors or memantine as long as stable on medication for 3 months or more 3. An adequate level of communication in written and verbal English

Exclusion criteria

Exclusion criteria: 1. Patients with alternative neurodegenerative diseases or other condition likely to interfere with test performance (e.g. chronic pain, stroke) 2. Patients on medication likely to interfere with cognitive performance that has been changed in the last 3 months 3. The tests of attention in this trial require a working knowledge of English, good vision and the ability to walk independently (with or without walking aids) and we will therefore exclude patients without sufficient English language skills, those with poor vision and those who cannot walk independently. 4. Patients taking caffeine containing medication or foodstuffs with greater than 15mg caffeine over a day who do not wish to cease ingestion 5. If a patient loses capacity to consent during the trial they will be withdrawn

Design outcomes

Primary

MeasureTime frame
Attention, measured by neuropsychological tests

Secondary

MeasureTime frame
1. Ability to complete a timed walk 2. Ability to complete a timed walking while talking task 3. The measure of habitual caffeine intake by patients with dementia and its correlation with hallucinations and sleeping patterns

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026